Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop

The recent approval by the FDA of the combination of anti-CTLA4 and anti-PD-1 mAbs for the treatment of BRAF-unmutated unresectable or metastatic melanoma is a landmark for the development of cancer immunotherapy. On October 18 to 22, 2015, a symposium was held in Pamplona (Spain) to present and dis...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer research (Chicago, Ill.) Vol. 76; no. 10; pp. 2863 - 2867
Main Authors:	Berraondo, Pedro, Ochoa, María Carmen, Rodriguez-Ruiz, María Esperanza, Minute, Luna, Lasarte, Juan José, Melero, Ignacio
Format:	Journal Article
Language:	English
Published:	United States 15-05-2016
Subjects:	Animals Antibodies, Monoclonal - therapeutic use CTLA-4 Antigen - antagonists & inhibitors CTLA-4 Antigen - immunology Humans Immunomodulation - drug effects Immunotherapy Melanoma - immunology Melanoma - secondary Melanoma - therapy Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - immunology Research Report
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The recent approval by the FDA of the combination of anti-CTLA4 and anti-PD-1 mAbs for the treatment of BRAF-unmutated unresectable or metastatic melanoma is a landmark for the development of cancer immunotherapy. On October 18 to 22, 2015, a symposium was held in Pamplona (Spain) to present and discuss the basic and clinical discoveries that have brought us to this milestone and to explore other targets and immunotherapy strategies aimed at attaining more efficacious oncology practice in the short term. Cancer Res; 76(10); 2863-7. ©2016 AACR.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0008-5472 1538-7445
DOI:	10.1158/0008-5472.CAN-15-3279